We use cookies on our site to track usage and preferences. Learn more

Healing and feeding the world

In the life sciences sector, companies are working on both medical and agricultural products and services.


The Park is currently home to 34 biomedical companies working on a wide range of products and technologies spanning disease prediction and prevention to diagnostics, treatment and patient monitoring. This number will increase significantly when the new 40,000 sq ft BioHub opens next year.

  • 12 companies are involved in the research and development of therapeutics. This includes small molecule drug discovery, biologics, immuno-therapies and generics across multiple disease areas
  • 7 companies specialise in medical products including non-invasive diagnostics and wearables
  • 14 companies are developing platform technologies or products and services for research scientists. These include suppliers of antibodies, informatics and data services, regulatory and technical consulting


In the agri-tech sector, the Park is home to companies working on crop protection products for professional farmers and growers.


The latest news, discoveries and innovations in life science

See all Life Sciences news

TWEET by @cerevance

We are pleased to announce that we were highly commended as #Biotech #CompanyOfTheYear at the @CambridgeIndy #ScienceTechnologyAwards last night! Check it out here: bit.ly/32iOdnd pic.twitter.com/XMIVAmwmop


Nuformix plc Positive Results for NXP001 Clinical Trial


Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board strengthening the company’s leadership team in preparation for scaling commercial operations internationally

TWEET by @Mogrify_UK

Mesenchymal stem cells are a common source cell type in the development of #celltherapy, this review by @Red_TerCel discusses the current status of #MSCs, their limitations & potential solutions to improve their therapeutic efficacy. @FrontCellDevBio: bit.ly/3sr9AND


Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test


Three UK biotechnology companies will combine research expertise to develop fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK.


Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio.


Rapid discovery and manufacture of next-generation cell therapies


KTP Grant Expedites Development of Nuclera’s Desktop Gene Printer


Qkine secures £1.5M series A funding from leading life science investors to accelerate global scale-up and make key hires to leadership team

Contact us

Thank you for your enquiry!
We'll be in touch soon.

We couldn't send your message.
Please review the fields then try again